Detalles de la búsqueda
1.
Qualitative interviews to understand health care providers' experiences of prescribing licensed peanut oral immunotherapy.
BMC Res Notes
; 15(1): 273, 2022 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35941597
2.
Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.
Allergy Asthma Clin Immunol
; 18(1): 37, 2022 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35534909
3.
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.
BioDrugs
; 36(1): 85-93, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34951696
4.
Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience.
Radiat Oncol
; 17(1): 160, 2022 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36163026
5.
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.
Inflamm Bowel Dis
; 27(8): 1346-1355, 2021 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33051647
6.
Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
Arthritis Res Ther
; 22(1): 4, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31910893
7.
One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Arthritis Res Ther
; 20(1): 2, 2018 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29329557
8.
Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.
Patient Prefer Adherence
; 12: 869-878, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872272
9.
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Clin Colorectal Cancer
; 10(4): 333-9, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22000810
10.
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Clin Colorectal Cancer
; 10(3): 171-7, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21855038
11.
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
J Clin Oncol
; 28(8): 1351-7, 2010 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20142600
Resultados
1 -
11
de 11
1
Próxima >
>>